This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Spero Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $81.81 Mil.
Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics EV-to-EBIT Related Terms
Spero Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spero Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's EV-to-EBIT falls into.
Spero Therapeutics's current Enterprise Value is $71.12 Mil.
Spero Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (SPRO) has a EV-to-EBIT of 5.02 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spero Therapeutics and its competitors. According to the industry distribution chart, Spero Therapeutics ranks #119 out of 364 companies in the Biotechnology industry, placing it in the top 32.7%.
Is Spero Therapeutics' EV-to-EBIT too high?
Spero Therapeutics' current EV-to-EBIT is 5.02. The Biotechnology industry median EV-to-EBIT is 14.55. Spero Therapeutics' value of 5.02 is 65.5% below this industry median. Based on the distribution chart, Spero Therapeutics ranks #119 out of 364 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spero Therapeutics has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' EV-to-EBIT compare to VXRT and ADCT?
According to the Biotechnology industry distribution chart, Spero Therapeutics ranks #119 out of 364 companies for EV-to-EBIT. This puts Spero Therapeutics in the upper half of its industry. The industry median EV-to-EBIT is 14.55. Spero Therapeutics' value of 5.02 is 65.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.55, based on 364 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spero Therapeutics's current EV-to-EBIT of 5.02 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Spero Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spero Therapeutics's current EV-to-EBIT is 5.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.05, compared to a current price of $2.16 — trading 105.2% above its estimated fair value. The current EV-to-EBIT is 5.02 and 65.5% below the Biotechnology industry median of 14.55. Spero Therapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Spero Therapeutics (SPRO), the current EV-to-EBIT is 5.02 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of $2.16 is trading 105.2% above its estimated GF Value™ of $1.05.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for SPRO:
EV-to-EBIT: 5.02
GF Value™: $1.05 vs. price of $2.16 (105.2% above fair value)
Industry Position: 65.5% below the Biotechnology median (#119 of 364)
No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score
Get the complete analysis for SPRO
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRO has been successfully added to your 
